1
0
0
(1 - 17 von 20
)
EJC | European Journal of Cancer | Vol 74, Pages (March 2017) |...
www.sciencedirect.com
Wolfram C.M. Dempke, Klaus Fenchel, Peter Uciechowski, Stephen P. Dale. Pages : Download PDF. Article preview. select article The majority of patients ...
Ludger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4 ...healthdocbox.com › Cancer › Ludger-sel...
healthdocbox.com
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in ...
Immunotherapies for NSCLC: Are We Cutting the Gordian ...IIAR Journals
ar.iiarjournals.org
WOLFRAM C.M. DEMPKE, LUDGER SELLMANN, KLAUS FENCHEL and KLAUS EDVARDSEN. Anticancer Research November 2015, 35 (11) ;. WOLFRAM C.M. DEMPKE.
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?ar.iiarjournals.org › content › tab-article-info
ar.iiarjournals.org
WOLFRAM C.M. DEMPKE,,; LUDGER SELLMANN⇑,; KLAUS FENCHEL and; KLAUS EDVARDSEN. 1University Hospital of Grosshadern (LMU Munich, Haematology and Oncology), ...
Cytotoxic drug extravasationNational Institutes of Health (.gov)
pubmed.ncbi.nlm.nih.gov
von K Fenchel · · Zitiert von: 16 — Affiliation. 1 Abteilung Hämatologie und internistische Onkologie, Justus-Liebig Universität, Giessen. .uni-giessen.de. von WCM Dempke · — Authors. Wolfram C M Dempke , Klaus Fenchel , Susanne Reuther , Michael F Murphy. Affiliations. 1 Worldwide Clinical Trials, Research Triangle Park, ... › ...
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? - PubMed
pubmed.ncbi.nlm.nih.gov
... Cutting the Gordian Helix? Anticancer Res Nov;35(11): Authors. Wolfram C M Dempke , Ludger Sellmann , Klaus Fenchel , Klaus Edvardsen ...
Efficacy and Safety of Approved First-Line Tyrosine Adis Journalsadisjournals.figshare.com › articles › figure › Efficacy_and_Safety_of_Ap...
adisjournals.figshare.com
posted on , 02:41 by Kirsi M. Manz, Klaus Fenchel, Andreas Eilers, Jonathan Morgan, Kirsten Wittling, Wolfram C. M. Dempke.
Has programmed cell death ligand-1 MET an accomplice in non-small...
pubmed.ncbi.nlm.nih.gov
Authors. Wolfram C M Dempke , Klaus Fenchel. Affiliations. 1 Department of Haematology and Oncology, University of Munich, Munich, Germany.
Improved overall survival following tyrosine kinase inhibitor ...pubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Authors. Klaus Fenchel , Stephen P Dale , Wolfram C M Dempke. Affiliations. 1 Medical School Hamburg (MSH), Hamburg, and Praxisklinik Saalfeld/Saale, ...
Targeting Developmental Pathways: The Achilles Heel of ...
pubmed.ncbi.nlm.nih.gov
von WCM Dempke · · Zitiert von: 22 — Authors. Wolfram C M Dempke , Klaus Fenchel, Peter Uciechowski, Timothy Chevassut. Affiliation. 1 Department of Haematology and Oncology, ... von K Fenchel · · Zitiert von: 16 — Affiliation. 1 Abteilung Hämatologie und internistische Onkologie, Justus-Liebig Universität, Giessen. .uni-giessen.de. › ...
Overall survival in non-small cell lung cancer-what is clinically...
pubmed.ncbi.nlm.nih.gov
Transl Lung Cancer Res Feb;5(1): doi: j.issn Authors. Klaus Fenchel , Ludger Sellmann , Wolfram C M Dempke ...
Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer...
go.gale.com
Gale Academic OneFile includes Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy by Wolfram C.M. Dempke, Peter Uciechowski,. Click to explore.
Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer...
go.gale.com
Authors: Wolfram C.M. Dempke, Peter Uciechowski, Klaus Fenchel and Timothy Chevassut. Date: Oct. 1, From: Oncology(Vol. 95, Issue 5). Publisher: S.
Alle Infos zum Namen "Klaus Fenchel"
sortiert nach Relevanz / Datum